Proprietary Technology to Be a Part of the $4 Billion Respiratory Therapy
Device Market
Ingen Technologies Begins Production of OxyView(TM)
YUCAIPA, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (OTC: IGTG), a medical device manufacturer and research developer of "next generation" medical technologies, announced today that production of its newest OxyView(TM) medical device has commenced. Deliveries are scheduled for October 2006.
Ingen's OxyView(TM) is a proprietary medical device that provides a visual signal of gas flow through a conduit. In particular, OxyView(TM) is a pneumatic flow meter that provides a visual cue, viewable with the human eye, as to the flow of gas through a cannula, which conventionally employs very low pressure and gas volume to the patient wearing it. The Company's proprietary device is adapted to be engaged between the nose or mouth-mounted cannula, where a compressed oxygen supply is delivered to the cannula through a flexible conduit. OxyView(TM) delivers an easily readable confirmation of actual continuous flow and volume of oxygen.
Ingen's OxyView(TM) application claims the benefit of U.S. Provisional Application Serial Number 60/780,980, filed on March 10, 2006. Patents have also been filed in Japan, Peoples Republic of China and in the European Communities in order to satisfy exclusive relationships with various over-seas distributors.
According to the most current government reports and public statistical data, respiratory diseases are increasingly common ailments in both advanced and developing countries. With some 8-9% of Americans suffering from asthma, Chronic Obstruction Pulmonary Disease (COPD), bronchitis or other respiratory conditions, the high incidence and prevalence has translated into a large market for disposable respiratory products of $15 billion worldwide in 2005 with 70% related to asthma. Excluding asthma inhalers, the market for respiratory therapy devices still exceeds $4 billion and is expected to grow at 10% CAGR to over $6 billion by 2010. Further, the studies indicate an increase of patients with COPD, who are a prime population for the continuous use of oxygen in hospitals, long term care facilities and in the home. Many innovative drugs and medical devices are in the pipeline to treat respiratory diseases. The Company has targeted these markets for the sale of OxyView(TM).
Ingen Technologies CEO and Chairman Scott Sand said, "With the long-awaited introduction of our OxyView(TM) product and the resulting production, the growth potential for Ingen and the benefits to our shareholders are greatly improved. OxyView(TM) is FDA Registered and Classified, and sells for $14.95. We look forward to a successful introduction."
It's about time
Posts: 69 | Registered: Dec 2005
| IP: Logged |
posted
well, i think this stock can really pop tomorrow. Not huge volume today but it was up 137%. I think more people will see this and buy. im think another couple good days then sell late friday.
Posts: 31 | From: Sacramento | Registered: Sep 2006
| IP: Logged |
quote:Originally posted by musky: well, i think this stock can really pop tomorrow. Not huge volume today but it was up 137%. I think more people will see this and buy. im think another couple good days then sell late friday.
posted
I have been trying to unload some shares all day. Every time I put my order in I see a trade go through for the same amount, the bid drops yet my trade does not go through. Any ideas as to what king of manipulation causes this? OBTW, I pulled my order as soon as I saw a drop below my limit price. This has happened 3 times now so it looks like there was some volume but I think it is too coincidental to have been 3x with my exact share #.
Posts: 368 | Registered: Oct 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
